Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

Children's Oncology Group

Status: Completed

Conditions: Ann Arbor Stage IV Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage III Childhood Hodgkin Lymphoma; Refractory Childhood Hodgkin Lymphoma

Treatments: Other: Cytology Specimen Collection Procedure

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT00900250

U10CA180886 (U.S. NIH Grant/Contract)

COG-AHOD04B1

U10CA098543 (U.S. NIH Grant/Contract)

CDR0000495369

NCI-2009-00378 (Registry Identifier)

AHOD04B1 (Other Identifier)

Details and patient eligibility

About

This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.

Full description

OBJECTIVES:

I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with Hodgkin's lymphoma.

II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy.

OUTLINE: This is a multicenter study.

Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.

Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.

Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.

Enrollment: 1,271 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:

  • Newly diagnosed, untreated HL (for patients under 22 years of age)
  • Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)

Trial design

1,271 participants in 1 patient group

Ancillary-correlative (specimen collection and baking)

Description:

Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression. Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression. Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.

Treatment:

Other: Cytology Specimen Collection Procedure